அமெரிக்கன் கலைக்கழகம் க்கு புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அமெரிக்கன் கலைக்கழகம் க்கு புற்றுநோய் ஆராய்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அமெரிக்கன் கலைக்கழகம் க்கு புற்றுநோய் ஆராய்ச்சி Today - Breaking & Trending Today

Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline


Share:
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 4, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021.
Molecular Partners continues to grow and expand the reach of our DARPin® therapeutics platform, with the COVID-19 pandemic forming a meaningful change agent for us, said Patrick Amstutz, Ph.D., chief executive officer of Molecular Partners. Twelve months ago, we were only at the initiating stages of our COVID-19 program, while this year we are approaching Phase 3 clinical trials with our partners at Novartis. I am extremely proud of our team and partners for not only bringing us to this stage of development in our new antiviral program, but also for continuing to advance our targeted oncology pipeline. ....

United States , Shai Biran , Seth Lewis , Thomas Schneckenburger , Patrick Amstutz , Agnete Fredriksen , Company Phase , Company Board Of Directors , American Academy For Cancer Research , National Institutes Of Health , Program Phase , Research Development , Molecular Partners , New Drug Application , Cancer Research , Annual Meeting , National Institutes , Molecular Partner , Half Year Results , ஒன்றுபட்டது மாநிலங்களில் , ஷாய் பிரன் , சேதி லெவிஸ் , பேட்ரிக் அம்சட்டுட்ஸ் , நிறுவனம் கட்டம் , நிறுவனம் பலகை ஆஃப் இயக்குநர்கள் , அமெரிக்கன் கலைக்கழகம் க்கு புற்றுநோய் ஆராய்ச்சி ,

Molecular Partners AG: Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline


(1)
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 4, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021.
Molecular Partners continues to grow and expand the reach of our DARPin® therapeutics platform, with the COVID-19 pandemic forming a meaningful change agent for us, said Patrick Amstutz, Ph.D., chief executive officer of Molecular Partners. Twelve months ago, we were only at the initiating stages of our COVID-19 program, while this year we are approaching Phase 3 clinical trials with our partners at Novartis. I am extremely proud of our team and partners for not only bringing us to this stage of development in our new antiviral program, but also for continuing to advance our targeted oncology pipeline. ....

United States , Shai Biran , Seth Lewis , Thomas Schneckenburger , Patrick Amstutz , Agnete Fredriksen , Company Phase , Company Board Of Directors , American Academy For Cancer Research , National Institutes Of Health , Program Phase , Research Development , Molecular Partners , New Drug Application , Cancer Research , Annual Meeting , National Institutes , Molecular Partner , Half Year Results , ஒன்றுபட்டது மாநிலங்களில் , ஷாய் பிரன் , சேதி லெவிஸ் , பேட்ரிக் அம்சட்டுட்ஸ் , நிறுவனம் கட்டம் , நிறுவனம் பலகை ஆஃப் இயக்குநர்கள் , அமெரிக்கன் கலைக்கழகம் க்கு புற்றுநோய் ஆராய்ச்சி ,